Alex Klarer

2 months ago | cellandgene.com | Alex Klarer |Amber Sherrick |Derek Pendlebury |Chris Hofmann

Introducing a new way to source solutions for improving, refining, and optimizing your CGT manufacturing! From April 8-10, Life Science Connect brings you the next virtual showcase from its network of trusted communities: Cell & Gene Therapy Tech Expo.

Jan 21, 2025 | cellandgene.com | Alex Klarer

By Alex Klarer, founder and managing director, Engelex The cell and gene therapy (CGT) industry is at the forefront of medical innovation, offering the promise of curing previously untreatable diseases but is faced with a complex value chain to convert raw materials into lifesaving treatments.

Nov 19, 2024 | outsourcedpharma.com | Louis Garguilo |Alex Klarer |Cory Lewis |Andy Moreo

As the pipeline of viral vector-based therapies continues to reach later stage studies, a standardized manufacturing process is necessary for chemistry, manufacturing, & control (CMC) requirements from regulatory agencies. Several of the challenges to standardize viral vector manufacturing include bottlenecks in the supply chain, lack of scalability in processes, and variability associated with customer-driven SOPs. Click here to learn more about Catalent’s UpTempoâ„  AAV platform solution.

Oct 23, 2024 | cellandgene.com | Alex Klarer

By Alex Klarer, Founder, Managing Director, Engelex The cell and gene therapy (CGT) industry has witnessed remarkable growth over the past decade, driven by groundbreaking scientific advancements and treatments for indications with high unmet needs. The industry got a boost in attention and investment during the pandemic in 2020 more than doubling the dollars investment from the previous year and seeing a 20% increase in clinical trials1.

Oct 23, 2024 | outsourcedpharma.com | Alex Klarer |Louis Garguilo

By Alex Klarer, Founder, Managing Director, Engelex The cell and gene therapy (CGT) industry has witnessed remarkable growth over the past decade, driven by groundbreaking scientific advancements and treatments for indications with high unmet needs. The industry got a boost in attention and investment during the pandemic in 2020 more than doubling the dollars investment from the previous year and seeing a 20% increase in clinical trials1.